Sana Biotechnology, Inc.(SANA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SANA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Sana Biotechnology, Inc. (SANA), a Healthcare sector company. SANA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Sana Biotechnology, Inc. reports net income of $-63.6M, free cash flow of $-34.4M. Top institutional holders of SANA by reported 13-F value include FMR, Flagship Pioneering, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. SANA trades on the Nasdaq exchange and files with the SEC under CIK 1770121. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SANA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sana Biotechnology, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-63.6M
Free Cash Flow
Q2 2026
$-34.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+8.5% YoYOperating Income
+8.2% YoYEPS (Diluted)
+17.2% YoYTotal Assets
-16.8% YoYOp. Cash Flow
+35.5% YoYFree Cash Flow
+43.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-244.2M +8.5% | $-266.8M +5.8% | $-283.3M -5.1% | $-269.5M +24.3% | $-355.9M -24.8% | $-285.3M |
| Operating Income | $-250.3M +8.2% | $-272.7M +7.0% | $-293.1M -7.5% | $-272.6M +23.6% | $-356.9M -24.7% | $-286.1M |
| EPS (Diluted) | $-0.96 +17.2% | $-1.16 +20.5% | $-1.46 -2.1% | $-1.43 +33.2% | $-2.14 -7.4% | $-1.99 |
| Total Assets | $416.9M -16.8% | $501.0M -11.4% | $565.3M -31.3% | $822.7M -27.2% | $1.13B +54.7% | $730.3M |
| Operating Cash Flow | $-143.8M +35.5% | $-223.2M +12.0% | $-253.6M +12.6% | $-290.1M -15.5% | $-251.1M -81.9% | $-138.0M |
| Free Cash Flow | $-144.8M +43.6% | $-256.6M +6.2% | $-273.6M +12.0% | $-310.9M -10.7% | $-280.9M -73.6% | $-161.9M |
Get alerted when SANA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Sana Biotechnology, Inc. including:
Top Institutional Holders of SANA
FMR LLC
$130.6M37,429,515 shFlagship Pioneering Inc.
$87.3M25,001,856 shRA CAPITAL MANAGEMENT, L.P.
$65.4M18,750,000 shBlackRock, Inc.
$58.2M16,675,173 shSTATE STREET CORP
$39.1M11,203,134 shCANADA PENSION PLAN INVESTMENT BOARD
$35.7M10,218,400 shVANGUARD CAPITAL MANAGEMENT LLC
$29.2M8,375,421 shBANK OF AMERICA CORP /DE/
$20.1M5,748,454 shGEODE CAPITAL MANAGEMENT, LLC
$16.3M4,677,959 shMarex Group plc
$13.9M3,989,100 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $130.6M | 37,429,515 |
| Flagship Pioneering Inc. | $87.3M | 25,001,856 |
| RA CAPITAL MANAGEMENT, L.P. | $65.4M | 18,750,000 |
| BlackRock, Inc. | $58.2M | 16,675,173 |
| STATE STREET CORP | $39.1M | 11,203,134 |
| CANADA PENSION PLAN INVESTMENT BOARD | $35.7M | 10,218,400 |
| VANGUARD CAPITAL MANAGEMENT LLC | $29.2M | 8,375,421 |
| BANK OF AMERICA CORP /DE/ | $20.1M | 5,748,454 |
| GEODE CAPITAL MANAGEMENT, LLC | $16.3M | 4,677,959 |
| Marex Group plc | $13.9M | 3,989,100 |
More Healthcare Companies
View all Healthcare →Put SANA on your watchlist
Track score changes the day Sana Biotechnology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SANA a good stock to buy?
13F Pro's AI-powered analysis of Sana Biotechnology, Inc. (SANA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SANA are available on the SANA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SANA is classified as a small company.
Which hedge funds own SANA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SANA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sana Biotechnology, Inc.'s investment landscape.